Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 5;10(15):3352-3360.
doi: 10.7150/jca.30691. eCollection 2019.

Low-Grade Endometrial Stromal Sarcoma and Uterine Adenosarcoma: A Comparison of Clinical Manifestations and Outcomes

Yanyan Zhang  1 , Yan Li  1 , Huifang Huang  1 , Jiaxin Yang  1 , Ming Wu  1 , Ying Jin  1 , Lingya Pan  1
Affiliations

Low-Grade Endometrial Stromal Sarcoma and Uterine Adenosarcoma: A Comparison of Clinical Manifestations and Outcomes

Yanyan Zhang et al. J Cancer. .

Abstract

Objective: Our study aimed to assess factors associated with progression free survival (PFS) and overall survival (OS) in low grade endometrial stromal sarcoma (LG-ESS) and uterine adenosarcoma, and to determine the differences in clinical manifestations and outcomes between the two diseases. Methods: A total of 132 patients were enrolled in this retrospective study at Peking Union Medical College Hospital from 1998 to 2016. The associations of clinical and pathological factors with PFS and OS were evaluated. Results: Of the 132 included patients, 104 had LG-ESS and 28 had uterine adenosarcoma. All patients were followed up for at least 1.5 years. There were significant differences between LG-ESS and uterine adenosarcoma in terms of age distribution (41.05±10.5 vs 46.11±14.96 years, P=0.042), delivery time (nulliparity=0: 18.27% vs 35.71%, P=0.046), history of the uterine leiomyoma (65.38% vs 39.29%, P=0.012), and polypoid tumor growth (14.42% vs 60.71%, P=0.007). According to the pathological findings, the proportion of uterine adenosarcoma patients with uterine leiomyoma (60.71%) was significantly higher than that for the LG-ESS patients (32.69%) (P=0.007). Uterine adenosarcoma seemed to be associated with longer PFS and OS than LG-ESS (PFS: 42.69±29.94 vs 50.50±40.50 months; OS: 58.72±37.29 vs 69.46±47.58 months), but the differences were not statistically significant. Multivariate Cox regression showed that age, menopause, history of uterine leiomyoma, stage, and hormone therapy were independent risk factors with respect to PFS, whereas age and stage were risk factors affecting OS in LG-ESS patient. Peritoneal lavage cytology and radiotherapy were risk factors affecting PFS and peritoneal lavage cytology for OS in patients with uterine adenosarcoma. Conclusion: The patients with advanced LG-ESS had poor prognosis. Age and history of uterine leiomyoma were associated with poor PFS, while menopause and hormone therapy were protective factors associated with improved PFS in patients with LG-ESS. Peritoneal lavage cytology and radiotherapy did not improve prognosis of uterine adenosarcoma.

Keywords: clinical manifestations; low-grade endometrial stromal sarcoma; prognosis; uterine adenosarcoma.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
PFS of patients (A) with LG-ESS and (B) with uterine adenosarcoma.
Figure 1
Figure 1
PFS of patients (A) with LG-ESS and (B) with uterine adenosarcoma.
Figure 2
Figure 2
PFS of patients with LG-ESS by (A) menopause (yes or no), (B) stage: (early or late), (C) hormone therapy (with or without), and (D) history of uterine leiomyoma.
Figure 2
Figure 2
PFS of patients with LG-ESS by (A) menopause (yes or no), (B) stage: (early or late), (C) hormone therapy (with or without), and (D) history of uterine leiomyoma.
Figure 2
Figure 2
PFS of patients with LG-ESS by (A) menopause (yes or no), (B) stage: (early or late), (C) hormone therapy (with or without), and (D) history of uterine leiomyoma.
Figure 2
Figure 2
PFS of patients with LG-ESS by (A) menopause (yes or no), (B) stage: (early or late), (C) hormone therapy (with or without), and (D) history of uterine leiomyoma.
Figure 3
Figure 3
PFS of patients with uterine adenosarcoma (A) with (negative or positive) or without peritoneal lavage cytology, and (B) with or without Radiotherapy.
Figure 3
Figure 3
PFS of patients with uterine adenosarcoma (A) with (negative or positive) or without peritoneal lavage cytology, and (B) with or without Radiotherapy.
Figure 4
Figure 4
OS of patients (A) patients with LG-ESS and (B) with uterine adenosarcoma
Figure 4
Figure 4
OS of patients (A) patients with LG-ESS and (B) with uterine adenosarcoma
Figure 5
Figure 5
OS of patients (A) LG-ESS in early or late stage and (B) uterine adenosarcoma with (negative or positive) or without peritoneal lavage cytology.
Figure 5
Figure 5
OS of patients (A) LG-ESS in early or late stage and (B) uterine adenosarcoma with (negative or positive) or without peritoneal lavage cytology.
See this image and copyright information in PMC

References

    1. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Human Pathology. 1990;21(4):363–81. - PubMed
    1. Nathenson MJ, Conley AP, Lin H. et al. Treatment of recurrent or metastatic uterine adenosarcoma. Sarcoma. 2017;2017:4680273. - PMC - PubMed
    1. Benson C, Miah AB. Uterine sarcoma - current perspectives. Int J Womens Health. 2017;9:597–606. - PMC - PubMed
    1. Agarwal R, Rajanbabu A, Nair IR. et al. Endometrial stromal sarcoma-A retrospective analysis of factors affecting recurrence. Eur J Obstet Gynecol Reprod Biol. 2017;216:92–7. - PubMed
    1. Chan JK, Kawar NM, Shin JY. et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99(8):1210–5. - PMC - PubMed

LinkOut - more resources